论文信息 - A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies. - 字舞流文

A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies.

I. Flinn | A. Wiestner | S. O'brien | S. Y. Kim | W. Wierda | A. Mato | W. Ai | M. Tees | S. Nandakumar | A. Danilov | M. Gessner | M. Patel | Michael Wang | K. Patel | M. Tan | E. Meredith